Cargando…
BCLX(L) gene therapy moderates neuropathology in the DBA/2J mouse model of inherited glaucoma
Axonal degeneration of retinal ganglion cells (RGCs) causes blindness in glaucoma. Currently, there are no therapies that target axons to prevent them from degenerating. Activation of the BAX protein has been shown to be the determining step in the intrinsic apoptotic pathway that causes RGCs to die...
Autores principales: | Donahue, Ryan J., Fehrman, Rachel L., Gustafson, Jenna R., Nickells, Robert W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355227/ https://www.ncbi.nlm.nih.gov/pubmed/34376637 http://dx.doi.org/10.1038/s41419-021-04068-x |
Ejemplares similares
-
Loss of Retinogeniculate Synaptic Function in the DBA/2J Mouse Model of Glaucoma
por: Smith, Jennie C., et al.
Publicado: (2022) -
Infection with flaviviruses requires BCLX(L) for cell survival
por: Suzuki, Tatsuya, et al.
Publicado: (2018) -
Early pro-inflammatory cytokine elevations in the DBA/2J mouse model of glaucoma
por: Wilson, Gina N., et al.
Publicado: (2015) -
The Contribution of Anterior Segment Abnormalities to Changes in Intraocular Pressure in the DBA/2J Mouse Model of Glaucoma: DBA/2J-Gpnmb(+)/SjJ Mice as Critical Controls
por: Rohowetz, Landon J., et al.
Publicado: (2022) -
BclX(L) (Bcl2l1) gene therapy lessens retinal ganglion cell soma loss but not axonal degeneration after acute axonal injury
por: Marola, Olivia J., et al.
Publicado: (2022)